N

Nashville Neuroscience Group | Bryant Research Group

Research site
(Unclaimed)
Location
2004 Hayes Street, Suite 650, Nashville, Tennessee, United States of America
Site insights

Top conditions

Migraine Disorders (17 trials)

Headache (3 trials)

Migraine with Aura (2 trials)

Migraine without Aura (1 trial)

Epilepsy (1 trial)

Top treatments

Atogepant
ABP-450
Erenumab
Sumatriptan
AMG334
LY2951742
Rimegepant
NXN-462
AGN-241689
Lasmiditan

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 18
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine...

Invitation-only
Migraine
Drug: ABP-450

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per m...

Active, not recruiting
Migraine
Drug: ABP-450
Drug: Placebo

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting
Episodic Migraine
Drug: BOTOX
Drug: Placebo

Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light a...

Enrolling
Chronic Migraine
Drug: Atogepant

Trial sponsors

Amgen logo

Amgen (3 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems